Intrinsic Bioprobes, of Tempe, Ariz.,a privately held biotechnology company, has licensed two novel biomarkers for diabetes to Ortho-Clinical Diagnostics, Inc., of Raritan, N.J.

Gambro, which has its U.S. headquarters in Lakewood, Colo., has acquired CHF Solutions, a privately held medical device company in Brooklyn Park, Minn., that manufactures and distributes ultrafiltration devices to treat fluid overload, both companies announced recently.

Fresenius Medical Care North America (FMCNA), headquartered in Waltham, Mass., has acquired Nashville-based Health IT Services Group and its portfolio of products, including Acumen nEHR, a nephrology-specific electronic health record.

Roche has received marketing clearance for Actemra (tocilizumab) as a treatment for moderate to severe active rheumatoid arthritis (RA) in adults who have had an inadequate response to one or more treatments that block tumor necrosis factor.

The FDA has issued a warning to consumers about a counterfeit and possibly harmful version of Alli 60 mg capsules (120 count refill kit). Alli is an over-the-counter weight-loss product.

Wyeth has notified health care professionals of changes to the Rapamune (sirolimus) prescribing information related to changes in the performance of an immunoassay used for therapeutic drug monitoring (TDM) of the medication, according to the FDA.

Watson Pharmaceuticals is voluntarily recalling one lot of 100 mcg/hr Fentanyl Transdermal System patches sold in the United States, according to a company press release.

A dozen hospitals in New Jersey and their affiliated physicians are participating in the Physician Hospital Collaboration Demonstration, a Medicare project to evaluate a program aimed at reducing health-care costs and improving quality of care.

Researchers recently treated the first patients who are participating in a phase 2 clinical trial of a novel therapy for benign prostatic hyperplasia (BPH).

Tekturna HCT, a single-pill combination of aliskiren—the first and only approved direct renin inhibitor—and hydrochlorothiazide (HCTZ) has been approved as initial therapy for patients who are likely to need multiple drugs to achieve their BP.